Skip to main content
Erschienen in: Clinical Journal of Gastroenterology 3/2018

30.01.2018 | Case Report

Two-step progression of varenicline-induced autoimmune hepatitis

verfasst von: Mitsuru Sakakibara, Kazuyoshi Ohkawa, Takatoshi Nawa, Yutaro Abe, Akira Kusakabe, Toshihiro Imai, Kazuhiro Katayama

Erschienen in: Clinical Journal of Gastroenterology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

We describe a rare case of drug-induced hepatitis due to the smoking cessation agent varenicline in a 46-year-old Asian woman. The liver injury progressed in two steps. First, the liver injury started in the absence of viral/autoimmune responses, and withdrawal of varenicline lowered the increase in the levels of liver enzymes immediately. Such findings suggested varenicline-induced liver injury. Second, hepatitis recurred in association with conversion of antinuclear antibody from negative to positive about 8 weeks after the initial episode. Histology upon recurrence of liver injury revealed interface hepatitis with lymphocytic and lymphoplasmacytic portal inflammatory infiltrates extending into lobules. Such findings suggested autoimmune hepatitis. Corticosteroid treatment was effective for recurrent hepatitis. The clinical course suggests that varenicline caused drug-induced liver injury and subsequent autoimmune hepatitis. Some autoimmune changes were probably involved in the mechanism of varenicline-induced liver injury.
Literatur
1.
Zurück zum Zitat Franck AJ, Sliter LR. Acute hepatic injury associated with varenicline in a patient with underlying liver disease. Ann Pharmacother. 2009;43:1539–43.CrossRefPubMed Franck AJ, Sliter LR. Acute hepatic injury associated with varenicline in a patient with underlying liver disease. Ann Pharmacother. 2009;43:1539–43.CrossRefPubMed
3.
Zurück zum Zitat Mogensen H, Björnsson ES. Varenicline-induced acute liver injury with jaundice. Hepatology. 2015;61:2110–1.CrossRefPubMed Mogensen H, Björnsson ES. Varenicline-induced acute liver injury with jaundice. Hepatology. 2015;61:2110–1.CrossRefPubMed
4.
Zurück zum Zitat Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52:730–42.CrossRefPubMedPubMedCentral Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52:730–42.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Stine JG, Northup PG. Autoimmune-like drug-induced liver injury: a review and update for the clinician. Exp Opin Drug Metab Toxicol. 2016;12:1–11.CrossRef Stine JG, Northup PG. Autoimmune-like drug-induced liver injury: a review and update for the clinician. Exp Opin Drug Metab Toxicol. 2016;12:1–11.CrossRef
6.
Zurück zum Zitat Watanabe M, Shibuya A. Validity study of a new diagnostic scale for drug-induced liver injury in Japan-comparison with two previous scales. Hepatol Res. 2004;30:148–54.CrossRefPubMed Watanabe M, Shibuya A. Validity study of a new diagnostic scale for drug-induced liver injury in Japan-comparison with two previous scales. Hepatol Res. 2004;30:148–54.CrossRefPubMed
7.
Zurück zum Zitat Lohse AW, Hennes E. Diagnostic criteria for autoimmune hepatitis. Hepatol Res. 2007;37(Suppl 3):S509.CrossRefPubMed Lohse AW, Hennes E. Diagnostic criteria for autoimmune hepatitis. Hepatol Res. 2007;37(Suppl 3):S509.CrossRefPubMed
8.
Zurück zum Zitat Murata Y, Ogawa Y, Saibara T, et al. Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis. Oncol Rep. 2003;10:97–100.PubMed Murata Y, Ogawa Y, Saibara T, et al. Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis. Oncol Rep. 2003;10:97–100.PubMed
9.
Zurück zum Zitat Ahbeddou N, Belbaraka R, Fetohi M, et al. Tamoxifen-induced hepatotoxicity. Indian J Cancer. 2011;48:385.CrossRefPubMed Ahbeddou N, Belbaraka R, Fetohi M, et al. Tamoxifen-induced hepatotoxicity. Indian J Cancer. 2011;48:385.CrossRefPubMed
10.
Zurück zum Zitat Takikawa H, Takamori Y, Kumagi T, et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. Hepatol Res. 2003;27:192–5.CrossRefPubMed Takikawa H, Takamori Y, Kumagi T, et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. Hepatol Res. 2003;27:192–5.CrossRefPubMed
11.
Zurück zum Zitat Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–38.CrossRefPubMed Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–38.CrossRefPubMed
12.
Zurück zum Zitat Weiler-Normann C, Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol. 2011;55:747–9.CrossRefPubMed Weiler-Normann C, Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol. 2011;55:747–9.CrossRefPubMed
13.
Zurück zum Zitat Iwamura S, Kojima Y, Ohka R, et al. Nidome no kanseiken de syouyou chuusintai eshi wo mitome, yakuzai kiinsei jikomenekisei kanen to shindan sita ichirei (A case of drug-induced autoimmune hepatitis demonstrated initial findings of centrilobular necrosis at the second liver biopsy). Kouchi Sekijuuji byouin Igaku Zasshi (Med J Kouchi Redcross Hospital) [published in Japanese]. 2016;21:39–44. Iwamura S, Kojima Y, Ohka R, et al. Nidome no kanseiken de syouyou chuusintai eshi wo mitome, yakuzai kiinsei jikomenekisei kanen to shindan sita ichirei (A case of drug-induced autoimmune hepatitis demonstrated initial findings of centrilobular necrosis at the second liver biopsy). Kouchi Sekijuuji byouin Igaku Zasshi (Med J Kouchi Redcross Hospital) [published in Japanese]. 2016;21:39–44.
14.
Zurück zum Zitat Bebo BF, Dehghani B, Foster S, et al. Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis. Glia. 2009;57:777–90.CrossRefPubMedPubMedCentral Bebo BF, Dehghani B, Foster S, et al. Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis. Glia. 2009;57:777–90.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Behfarjam F, Sanati MH, Nasseri Moghaddam S, et al. Role of Th1/Th2 cells and related cytokines in autoimmune hepatitis. Turk J Gastroenterol. 2017;28:110–4.CrossRefPubMed Behfarjam F, Sanati MH, Nasseri Moghaddam S, et al. Role of Th1/Th2 cells and related cytokines in autoimmune hepatitis. Turk J Gastroenterol. 2017;28:110–4.CrossRefPubMed
Metadaten
Titel
Two-step progression of varenicline-induced autoimmune hepatitis
verfasst von
Mitsuru Sakakibara
Kazuyoshi Ohkawa
Takatoshi Nawa
Yutaro Abe
Akira Kusakabe
Toshihiro Imai
Kazuhiro Katayama
Publikationsdatum
30.01.2018
Verlag
Springer Japan
Erschienen in
Clinical Journal of Gastroenterology / Ausgabe 3/2018
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-018-0824-x

Weitere Artikel der Ausgabe 3/2018

Clinical Journal of Gastroenterology 3/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.